A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults.
Hemme J HijmaPieter S SiebengaMarieke L de KamGeert Jan GroeneveldPublished in: Pain medicine (Malden, Mass.) (2021)
Results of this proof-of-mechanism study are supportive of the potential of VX-150, a highly selective NaV1.8 channel inhibitor, to treat various pain indications.